Sort   by:  
 Page size 

In our investigation, we examined biochemical parameters and identified hydroxybutyrate dehydrogenase (HBDH) as a significant predictor for diffuse large B-cell lymphoma (DLBCL) patients. A group of 100 patients was used to explore potential biomarkers related to progression-free survival (PFS). ...

2024-09-02 | MTBLS10446 | MetaboLights
Timing-dependent tryptophan diets differentially modulate DLBCL outcomes via microbiota-derived 3-IAA (pre-inoculation, anti-tumor) versus 5-HTP (post-inoculation, pro-tumor), with pectin restoring microbial balance to enable a timed tryptophan-pectin precision nutrition strategy for enhanced immuno...
2026-09-07 | MTBLS15570 | MetaboLights
Correct classification of cancer patients into subtypes is a prerequisite for acute diagnosis and effective treatment. Currently this classification relies mainly on histological assessment, but gene expression analysis bymicroarrays has shown great promise. Here we show that high accuracy, quantita...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2016-03-10 | MSV000079572 | MassIVE
Characterization of tumors at the molecular level has improved our knowledge of cancer causation and progression. Proteomic analysis of their signaling pathways promises to enhance our understanding of cancer aberrations at the functional level, but this requires accurate and robust tools. Here, we ...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-03-30 | MSV000080813 | MassIVE
Ferroptosis is a form of regulated cell death that can be induced by inhibition of the cystine-glutamate antiporter, system xc-. Among the existing system xc- inhibitors, imidazole ketone erastin (IKE) is a potent, metabolically stable inhibitor of system xc- and inducer of ferroptosis potentially s...
2019-04-17 | MTBLS774 | MetaboLights
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in natural history refle...
ORGANISM(S): Homo sapiens 
Data from ProteomeXhchange, PXD ID: PXD002098. Experiment: TMD8(2), file: folder summary. Published as part of Mol Cell Proteomics. 2012 May;11(5):77-89 . From the Abstract: {{i}} ... Here we show that high accuracy, quantitative proteomics can robustly segregate cancer subtypes directly at the lev...
ORGANISM(S): Homo_sapiens_viruses, Human 
Diffuse Large B-Cell Lymphoma (DLBCL) is a biologically heterogeneous and clinically aggressive disease. Here, we explore the role of BET bromodomain proteins in DLBCL, using integrative chemical genetics and functional epigenomics. We observe highly asymmetric loading of BRD4 at enhancers, with app...
ORGANISM(S): Homo sapiens 
Data from ProteomeXchange, PXD ID: PXD002052. Experiment: TRR37, file: folder summary. Published as part of Mol Cell Proteomics. 2015 Aug 26 . From the Abstract: {{i}} ... Here, we develop a state of the art quantitative mass spectrometric pipeline to characterize formalin-fixed paraffin-embedded (...
ORGANISM(S): Homo_sapiens_viruses, Human 
Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is curable in less than 50% of patients. Prognostic models based on pre-treatment characteristics, such as the International Prognostic Index (IPI), are currently used to predict outcome in DLBCL. However, clinical...
ORGANISM(S): Homo sapiens 
Sort   by:  
 Page size